Literature DB >> 12945079

Prospective study of peritoneal recurrence after curative surgery for gastric cancer.

F Roviello1, D Marrelli, G de Manzoni, P Morgagni, A Di Leo, L Saragoni, A De Stefano.   

Abstract

BACKGROUND: Peritoneal carcinomatosis is a common cause of failure after surgery for gastric cancer. The present longitudinal study was designed to evaluate the incidence and potential predictors of peritoneal recurrence after curative resection for gastric cancer.
METHODS: Four hundred and forty-one patients who underwent potentially curative resections for gastric cancer in three surgical centres between 1988 and 1996 were evaluated. All patients were followed using a standard protocol following discharge from hospital. The correlation between tumour recurrence and clinicopathological variables was studied by univariate and multivariate analyses.
RESULTS: Gastric cancer recurred in 215 (49 per cent) of 441 patients. Peritoneal recurrence was observed in 77 patients (17 per cent), locoregional recurrence in 96 patients and haematogenous recurrence in 75. Multivariate logistic regression analysis of factors associated with peritoneal recurrence identified diffuse-mixed histological type (relative risk (RR) 4.31, P < 0.001), infiltration of the serosa (RR 3.36, P = 0.001), lymph node involvement (RR 2.67, P = 0.023) and tumour size (RR 1.11, P = 0.050) as significant independent variables. In the diffuse-mixed histological subtype, the 5-year cumulative risk of peritoneal recurrence was 12 per cent in the absence of serosal invasion, and 69 per cent in patients with infiltration of the serosa; in the intestinal subtype, the cumulative risk in patients with serosa-negative and -positive tumours was 4 and 21 per cent respectively.
CONCLUSION: Radical surgery offers a low probability of cure in patients with diffuse-mixed type of gastric cancer and involvement of the serosa, due to a high risk of peritoneal recurrence. These patients might benefit from adjuvant therapies to prevent peritoneal carcinomatosis. Copyright 2003 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2003        PMID: 12945079     DOI: 10.1002/bjs.4164

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  75 in total

1.  Clinical implication of serosal change in pathologic subserosa-limited gastric cancer.

Authors:  Joo Mee Kim; Hun Jung; Jun Suh Lee; Han Hong Lee; Kyo Yung Song; Cho Hyun Park; Myung Hae Jeon
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

Review 2.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.

Authors:  Ramakrishnan Ayloor Seshadri; Olivier Glehen
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

3.  Late-onset peritoneal recurrence of advanced gastric cancer 20 years after primary resection.

Authors:  Yoshinaga Okugawa; Yuji Toiyama; Yasuhiro Inoue; Susumu Saigusa; Minako Kobayashi; Koji Tanaka; Yasuhiko Mohri; Chikao Miki; Masato Kusunoki
Journal:  World J Surg Oncol       Date:  2010-11-24       Impact factor: 2.754

4.  How does epidemiological and clinicopathological features affect survival after gastrectomy for gastric cancer patients-single Egyptian center experience.

Authors:  Ehab El Hanafy; Ayman El Nakeeb; Helmy Ezzat; Emad Hamdy; Ehab Atif; Tharwat Kandil; Amgad Fouad; Mohamed Abdel Wahab; Ahmed Monier
Journal:  World J Gastrointest Surg       Date:  2016-06-27

5.  Establishment and identification of a rabbit model of peritoneal carcinomatosis from gastric cancer.

Authors:  Lie-Jun Mei; Xiao-Jun Yang; Li Tang; Alaa Hammed Al-Shammaa Hassan; Yutaka Yonemura; Yan Li
Journal:  BMC Cancer       Date:  2010-04-01       Impact factor: 4.430

6.  Investigation of the recurrence patterns of gastric cancer following a curative resection.

Authors:  Jingyu Deng; Han Liang; Dianchang Wang; Dan Sun; Yi Pan; Yong Liu
Journal:  Surg Today       Date:  2011-01-26       Impact factor: 2.549

7.  Lymph node involvement in gastric cancer for different tumor sites and T stage: Italian Research Group for Gastric Cancer (IRGGC) experience.

Authors:  Alberto Di Leo; Daniele Marrelli; Franco Roviello; Marco Bernini; AnnaMaria Minicozzi; Simone Giacopuzzi; Corrado Pedrazzani; Luca Gian Baiocchi; Giovanni de Manzoni
Journal:  J Gastrointest Surg       Date:  2007-09       Impact factor: 3.452

8.  Adjuvant chemoradiotherapy versus adjuvant chemotherapy for R1 resected gastric cancer: a retrospective cohort study.

Authors:  Meng-Long Zhou; Gui-Chao Li; Wang Yang; Wei-Juan Deng; Ran Hu; Yan Wang; Zi-Wen Long; Xiao-Wen Liu; Ya-Nong Wang; Zhen Zhang
Journal:  Br J Radiol       Date:  2018-06-27       Impact factor: 3.039

9.  Resection line involvement after gastric cancer surgery: clinical outcome in nonsurgically retreated patients.

Authors:  P Morgagni; D Garcea; D Marrelli; G De Manzoni; G Natalini; H Kurihara; A Marchet; L Saragoni; E Scarpi; C Pedrazzani; A Di Leo; F De Santis; V Panizzo; D Nitti; F Roviello
Journal:  World J Surg       Date:  2008-12       Impact factor: 3.352

10.  Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from pseudomyxoma peritonei.

Authors:  Tommaso Cioppa; Marco Vaira; Camilla Bing; Silvia D'Amico; Alessandro Bruscino; Michele De Simone
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.